Innovation & Collaboration

In new markets, we aim to develop a strong formulation and manufacturing capabilities to establish ourselves as early generic players in the market.


In addition, we will increase our business development capabilities to identify new niche market segments. Fahrenheit plans to expand its influence internationally with other pharmaceutical industries, particularly on hospital and niche products. We will create strong bonds with our partners overseas in a way that is beneficial to our partners and to ourselves. Below are some examples as a result of our collaboration

Platelet aggregation inhibitor
Agrylin (Anagrelide), launch since 2004
Phosphate binder non calcium
Fosrenol (Lanthanum Carbonate), launch since 2009
General inhalation anesthetic
Terrell (Isoflurane), launch since 2006
Sojourn (Sevoflurane), launch since 2007
Low Molecular Weight Iron Dextran
Cosmofer (Iron Dextran), launch since 2008
Nano NSAID
Zorvolex (nano diclofenac)
Tivorbex (nano indomethacin)
Vivlodex (nano meloxicam)
High Potency Product / Oncology
Hepatitis C
Hepcinat (Sofosbuvir) - Under registration
Sofosbuvir + Ledispavir - Under registration